MedTrace Logo

Chondromodulating Effect of Diacerein in Osteoarthritis of the Hip

NCT00451360 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2008-07-25

No results posted yet for this study

Summary

We carried out a 3 years, randomized, double-blind, placebo-controlled, multicenter clinical trial in patients with hip osteoarthritis in order to:

* evaluate the ability of diacerein, an interleukin-1β inhibitor, to slow the progressive decrease in joint space width observed in patients with hip osteoarthritis
* to investigate the potential structure-modifying effect of diacerein in patients with hip osteoarthritis

This study compare also after ten years the percentage of patients in each treatment group who require a hip replacement surgery

Conditions

  • Hip Osteoarthritis

Interventions

DRUG

diacerein

Sponsors & Collaborators

  • Laboratoires NEGMA

    lead INDUSTRY

Principal Investigators

  • DOUGADOS Maxime · Scientific committee

  • Michel LEQUESNE · Scientific committee

  • Bernard MAZIERE · Scientific committee

  • Eric VIGNON · Scientific committee

  • Laurent BERDAH · Scientific committee

  • Minh NGUYEN

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1993-03-31
Completion
1997-04-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00451360 on ClinicalTrials.gov